Accessibility Menu
Star Combo Pharma logo

Star Combo Pharma(ASX) S66

Market CapA$18.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-82%
5 Year-57%
1 Year-14%
1 Month+17%
A$0.14
+7.69%
+0.01Today
Star Combo Pharma last closing stock price
MetricPriceDate
Last closeAUD 0.142026-08-25
Star Combo Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+12%AUD 0.132026-08-18
1 month+16.67%AUD 0.122026-07-24
3 month-28.21%AUD 0.202026-05-26
Year to date-46.15%AUD 0.262025-12-31
1 year-13.73%AUD 0.162025-08-25
3 year+32.47%AUD 0.112023-08-25
5 year-57.14%AUD 0.332021-08-26
Since inception-81.56%AUD 0.762018-05-16

Star Combo Pharma Financials at a Glance

Market Cap

A$18.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$51.38M

Net Income (TTM)

A$5.64M

EPS (TTM)

A$0.00

P/E Ratio

3.51

Dividend

A$0.00

Beta (Volatility)

-0.09 (Low)

Price

A$0.14

Volume

0

Open

A$0.14

Previous Close

A$0.14

Daily Range

A$0.14 - A$0.14

52-Week Range

A$0.10 - A$0.28

Estimated Earnings Date

Feb 24, 2026

S66 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Star Combo Pharma

Star Combo Pharma Limited is a dynamic player in the health foods and dietary supplements sector, operating primarily in Australia and China. The company specializes in the development, manufacturing, and distribution of natural health supplements and skincare products through its two main divisions: Star Combo and Austoyou Retail.

Products and Services
  • Health foods and dietary supplements tailored for health-conscious consumers
  • Skincare products developed with a focus on natural ingredients
  • E-commerce platform catering to the Chinese market alongside physical retail stores
Growth Outlook
  • Expansion into the Chinese market presents significant growth opportunities
  • Increasing consumer demand for health and wellness products supports revenue potential
  • Strategic investments in e-commerce are expected to enhance market reach
Financial Highlights
  • Recent quarterly revenue of 11.64 million AUD reflects strong market presence
  • Trailing twelve months (TTM) revenue of 47.73 million AUD indicates consistent performance
  • Current ratio of 3.86 suggests strong liquidity and financial stability
Star Combo Pharma Limited has established itself as a key player in the health and wellness industry, leveraging its dual market presence in Australia and China. The company's focus on natural health products aligns with growing consumer trends towards wellness and sustainability. Recent financial performance highlights a solid revenue stream, with a notable current ratio indicating robust liquidity. The strategic emphasis on e-commerce and market expansion positions Star Combo for future growth, making it an intriguing option for investors interested in the health sector.
AI Generated • Aug 25, 2026

Industry

Personal Products

CEO

Su Zhang, MBA

Headquarters

Smithfield, NSW 2164, AU

S66 Financials

Key Financial Metrics (TTM)

Gross Margin

21.17%

Operating Margin

-0.98%

Net Income Margin

1.67%

Return on Equity

1.02%

Return on Capital

-0.54%

Return on Assets

0.79%

Earnings Yield

28.49%

Dividend Yield

2.64%

Payout Ratio

1.27%

Stock Overview

Market Cap

A$18.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

135.00M

Volume

0

Avg. Volume

32.33K

Financials (TTM)

Gross Profit

A$11.26M

Operating Income

-A$416.16K

EBITDA

A$7.88M

Operating Cash Flow

A$15.22M

Capital Expenditure

-A$2.85M

Free Cash Flow

A$12.37M

Cash & ST Invst.

A$18.01M

Total Debt

A$4.19M

Star Combo Pharma Performance Analysis

Star Combo Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 24,700,2778.0%
20242024-06-30AUD 26,019,1015.3%
20252025-06-30AUD 27,811,5486.9%
20262026-06-30AUD 23,573,050-15.2%
Star Combo Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3015.4%
Q42025-06-30-25.2%
Q22025-12-310.2%
Q42026-06-30-2.4%
Star Combo Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.03469.2%
20242024-06-30AUD 0.01N/A
20252025-06-30AUD 0.04607.3%
20262026-06-30AUD 0.00-92.5%
Star Combo Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-30-56.5%
Q42025-06-301300.0%
Q22025-12-31-88.9%
Q42026-06-30-106.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$11.64M

-15.6%

Gross Profit

A$2.46M

-14.0%

Gross Margin

21.16%

N/A

Market Cap

A$18.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$630.01K

N/A

Employees

30

N/A

Net Income

-A$18.64K

-103.0%

EBITDA

A$690.47K

-36.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$18.01M

+144.8%

Total Debt

A$4.19M

+4.0%

Accounts Receivable

A$3.35M

-25.3%

Inventory

A$3.42M

-46.0%

Long Term Debt

A$3.89M

+0.5%

Short Term Debt

A$299.54K

+91.3%

Return on Assets

0.79%

N/A

Return on Invested Capital

-0.53%

N/A

Free Cash Flow

A$542.94K

+133.1%

Operating Cash Flow

A$2.70M

+428.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HCT.AXHolista Colltech Limited
A$0.05+2.08%
MCP.AXMcPherson's Limited
A$0.14+2.19%
ZNO.AXZoono Group Limited
A$0.05+0.00%
MBH.AXMaggie Beer Holdings Limited
A$0.06-4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
CRECre8 Enterprise
$6.60+1.57%
BITOProShares Trust - ProShares Bitcoin ETF
$10.50-0.01%
NVDANvidia
$210.97-0.01%
DAICCid HoldCo
$5.15+0.33%

Questions About S66

What is the current price of Star Combo Pharma?

Star Combo Pharma is trading at A$0.14 per share.

What is the 52-week range for Star Combo Pharma?

Over the past 52 weeks, Star Combo Pharma has traded between A$0.10 and A$0.28.

How much debt does Star Combo Pharma have?

As of the most recent reporting period, Star Combo Pharma reported total debt of A$4.19M.

How much cash does Star Combo Pharma have on hand?

Star Combo Pharma reported A$3.91M in cash and cash equivalents in its most recent financial results.

What is Star Combo Pharma’s dividend yield?

Star Combo Pharma currently has a dividend yield of 2.64%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.